Abstract： Objective： To observe the clinical effect of Shengmai capsules for patients with chronic heart failure due to coronary heart disease. Methods：A total of 90 cases of patients with chronic heart failure due to coronary heart disease were randomly divided into the control group and the observation group，45 cases in each group. The control group was treated with aspirin，benazepril，spironolactone and betaloc；the observation group was additionally treated with Shengmai capsules based on the treatment of the control group. Both groups were treated for eight weeks. The clinical effect and heart function in the two groups were evaluated. Before and after treatment，the values of nitric oxide(NO)，type B natriuretic peptide(BNP)， endothelin(ET) and left ventricular ejection fraction(LVEF) in the two groups were detected；the six-minute walking distances in the two groups were measured；the quality of life in the two groups was evaluated. During treatment，adverse reactions were recorded. Results：The total clinical effective rate in the observation group was higher than that in the control group(P＜ 0.05). The total effective rate of heart function improvement in the observation group was higher than that in the control group(P＜0.05). After treatment， the levels of BNP， NO and ET in the two groups were decreased when compared with those before treatment，and the decrease in the observation group was more significant than that in the control group；LVEF in the two groups was increased when compared with that before treatment， and the LVEF in the observation group was higher than that in the control group， the difference being significant(P＜0.05). After treatment， six- minute walking distances in the two groups were lengthened when compared with those before treatment， and the distance in the observation group was significantly longer than that in the control group， the difference being significant(P＜0.05). After treatment，the quality of life in the two groups was improved when compared with that before treatment，and the score of quality of life in the observation group was higher than that in the control group， the difference being significant(P＜0.05). During treatment， there was no obvious adverse reaction. Conclusion： Based on western medicine， the application of Shengmai capsules for chronic heart failure due to coronary heart disease can significantly enhance the curative effect，better improve the levels of heart function and endovascular related factors in patients， delay the progress of heart failure， and improve the quality of life.